BioCentury
ARTICLE | Clinical News

Auriclosene: Development discontinued

September 1, 2014 7:00 AM UTC

NovaBay discontinued development of an ophthalmic formulation of auriclosene to treat adenoviral conjunctivitis after the product given for 10 days missed the primary and secondary endpoints vs. vehicle in the double-blind, international Phase IIb BAYnovation trial in 500 patients. The primary endpoint was clearing of bulbar conjunctival injection and secondary endpoints included eradication of adenovirus from the tear film, spread of infection to the fellow eye, reduction in sub-epithelial infiltrates and clearing of blurred vision at the TOC visit at day 18. The company declined to disclose detailed data.

NovaBay said it will focus on developing an irrigation solution of auriclosene that is slated to start a second Phase II trial this quarter to reduce blockage and encrustation in indwelling long-term urinary catheters. Additionally, the company said it will continue developing auriclosene to treat impetigo and bacterial conjunctivitis. NovaBay said it also will focus on the ongoing U.S. launch of a lid and lash cleanser, as well as supporting partner China Pioneer Pharma Holdings Ltd. (HKSE:1345, Shanghai, China) with the Chinese launch of wound cleanser NeutroPhase, pending the product’s approval in the country, which is expected in 4Q14. ...